Literature DB >> 9010257

The effects of vitamin A derivatives on in vitro antibody production by peripheral blood mononuclear cells (PBMC) from normal blood donors and patients with common variable immunodeficiency (CVID).

J G Zhang1, L Morgan, G P Spickett.   

Abstract

The underlying nature of the defect of CVID is not understood, and the treatment at present is life-long infusion of replacement immunoglobulin. Attempts have been made to use other therapeutic agents, such as IL-2 and retinoic acid (RA), with mixed results. RA is a morphogenetic signalling molecule related to vitamin A and involved in vertebrate development. We report here our in vitro evaluation of the effects of three vitamin A analogues, 9-cis retinal, 13-cis RA and all-trans RA, on antibody production of PBMC from normal donors and patients with CVID. At 10(-5) M, 9-cis retinal strongly augmented IgM production of lymphocytes from normal individuals and to a much lesser extent, mild, non-granulomatous (group C) CVID patients, but IgG production was not affected. In the presence of anti-human IgM and IL-2, 9-cis retinal at 10(-5) M elevated IgM and IgG production by normal PBMC, but the effect on PBMC of mild CVID was minimal. The effect of 9-cis retinal was significantly reduced at 10(-7) and 10(-9) M. Only minimal effects were found using 13-cis RA and all-trans RA under these conditions. No detectable antibody production was found in severe, granulomatous (group A) CVID patients under any conditions tested. Taking all data into account, 9-cis retinal is the most potent stimulator for antibody production compared with 13-cis RA and all-trans RA as tested in this in vitro study.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9010257      PMCID: PMC1904540          DOI: 10.1046/j.1365-2249.1997.d01-893.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  4 in total

Review 1.  Integrative medicine in allergy and immunology.

Authors:  Christopher Chang; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2013-06       Impact factor: 8.667

Review 2.  Therapeutic strategies in common variable immunodeficiency.

Authors:  W A Carrock Sewell; Matthew Buckland; Stephen R A Jolles
Journal:  Drugs       Date:  2003       Impact factor: 9.546

3.  Antioxidative capacity in patients with common variable immunodeficiency.

Authors:  J Reichenbach; R Schubert; C Schwan; K Müller; H J Böhles; S Zielen
Journal:  J Clin Immunol       Date:  2000-05       Impact factor: 8.317

4.  Vitamin a deficiency in patients with common variable immunodeficiency.

Authors:  Sara Sebnem Kilic; Esra Yapici Kezer; Yesim Ozarda Ilcol; Tahsin Yakut; Sami Aydin; Ismail Hakki Ulus
Journal:  J Clin Immunol       Date:  2005-05       Impact factor: 8.317

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.